PRESS RELEASE

Obalon Balloon System Data to be Featured in Presentation During 35th ASMBS Annual Meeting at Obesity Week 2018

Clinical results from over 1,300 patients at 108 sites treated with Obalon’s novel weight loss device solution in commercial use

SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that clinical data for the Obalon Balloon System in commercial use in over 1,300 patients at 108 sites will be featured in an oral presentation at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting at Obesity Week 2018, being held November 11-15, 2018 in Nashville, TN. The data will be presented by Dr. Rachel Moore on November 14, 2018 at 5:00 pm (details below). Obalon believes this to be largest, single, consecutive data set ever presented on the commercial use of an intragastric balloon.

“We believe we have a novel, differentiated solution for weight loss that is performing as intended in actual commercial practice,” said Amy VandenBerg, Vice President of Clinical and Regulatory Affairs. “We are pleased to have data on the Obalon Balloon presented by Dr. Moore in a scientific forum at the largest medical meeting focused on obesity and believe the results validate the potential of the Obalon Balloon to impact the obesity epidemic.”

Details for the ASMBS oral presentation are as follows:

Title:The First Six Months of Commercial Experience with a Swallowable Gas-filled Three Balloon System Results in Safe and Clinically Meaningful Weight Loss (206764)
Session Title: Scientific Session
Date and Time:Wednesday, November 14, 2018, 5:05 p.m. - 5:15 p.m. CDT
Location: Music City Center

About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Obalon Therapeutics, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause Obalon Therapeutics' future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the product research, development and regulatory process and risks. Obalon Therapeutics undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Obalon Therapeutics' business in general, please refer to Obalon Therapeutics’ quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 2, 2018, and its current and future periodic reports filed with the Securities and Exchange Commission.

For Obalon Therapeutics, Inc.

Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com

Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com

Obalon_Logo_Teal_2c.jpg

Source: Obalon Therapeutics, Inc.

IMPORTANT SAFETY INFORMATION
The Obalon Balloon System is intended for adults with a body mass index (BMI) of 30 to 40 kg/m2 willing to follow a diet and exercise program. All Obalon balloons must be removed in 6 months. Patients with prior weight loss surgeries are not eligible. The most common side effects reported were mild abdominal pain and nausea which typically resolved within two weeks. You must take daily acid-blocking medicine prescribed by your doctor. For full Important Safety Information click onSafety Information and Patient Labeling